Albert Labs International (FRA:VB50) Debt-to-Asset : 0.16 (As of Sep. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Albert Labs International Debt-to-Asset?

Albert Labs International FRA:VB50 Debt-to-Asset is 0.16 as of Sep. 2023.

Albert Labs International's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was €0.00 Mil. Albert Labs International's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was €0.01 Mil. Albert Labs International's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Sep. 2023 was €0.05 Mil. Albert Labs International's debt to asset for the quarter that ended in Sep. 2023 was 0.16.


Albert Labs International  (FRA:VB50) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Albert Labs International Debt-to-Asset Related Terms


Albert Labs International Debt-to-Asset Historical Data

* Premium members only.

The historical data trend for Albert Labs International's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Albert Labs International Debt-to-Asset Chart

Albert Labs International Annual Data
Trend Dec21 Dec22
Debt-to-Asset
0.00 0.00

Albert Labs International Quarterly Data
Mar21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.16

FRA:VB50 vs VRTX, REGN, SGEN: Debt-to-Asset Comparison

For the Biotechnology subindustry, Albert Labs International's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Albert Labs International Debt-to-Asset vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Albert Labs International's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Albert Labs International's Debt-to-Asset falls into.



Albert Labs International Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Albert Labs International's Debt-to-Asset for the fiscal year that ended in Dec. 2022 is calculated as

Albert Labs International's Debt-to-Asset for the quarter that ended in Sep. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Asset →
What does a Debt-to-Asset of 0.16 mean?
Albert Labs International (FRA:VB50) has a Debt-to-Asset of 0.16 as of Sep. 2023. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Albert Labs International and its competitors.
Is Albert Labs International's Debt-to-Asset too high?
Albert Labs International's current Debt-to-Asset is 0.16.
How does Albert Labs International's Debt-to-Asset compare to VRTX and REGN?
Albert Labs International's Debt-to-Asset of 0.16 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Asset for a Biotechnology company?
A good Debt-to-Asset depends on the Biotechnology industry context. However, Debt-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Asset mean?
A high Debt-to-Asset can signal that a stock is expensive relative to its fundamentals. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Albert Labs International and its competitors. Albert Labs International's current Debt-to-Asset is 0.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Albert Labs International stock overvalued right now?
Albert Labs International (FRA:VB50) has a current Debt-to-Asset of 0.16. The current Debt-to-Asset is 0.16. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Asset calculated?
Debt-to-Asset is calculated from a company's financial statements. For Albert Labs International (FRA:VB50), the current Debt-to-Asset is 0.16 as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Albert Labs International Business Description

Address 201-6996 Merritt Avenue, Burnaby, BC, CAN, V5J 4R6
Albert Labs International Corp is a laboratory-based, clinical research, and drug development enterprise addressing mental health care needs. The company is focusing on Real World Evidence (RWE) the company will initially look to commercialize its mycelium-based KRN-101 medicine and treatment with the help of a clinical pathway.